

# Antimicrobial resistance research, funding and incentives – get updates next week in London at SMi event

LONDON, NON UNITED STATES OR CANADA, UNITED KINGDOM, March 15, 2018 /EINPresswire.com/ -- SMi reports: Antimicrobial resistance was predicted by Alexander Fleming in his Nobel lecture (1945). Since that warning, measures have been taken in acknowledgement of the threat of AMR, but tackling this issue is still an ongoing battle. On the global scale WHO has been the most instrumental body to take action. SMi Group is proud to be part of the fight with the [Superbugs & Superdrugs Conference](#). Now in its 20th year, the event has firmly become established as the industry's premier platform for updates on antimicrobial resistance research, funding and incentives.

The image is a promotional banner for the SMi's 20th Annual Conference. It features a dark background with a microscopic view of various bacteria in shades of purple and blue. The text is overlaid on the image. At the top right is the SMi logo. The main title 'Superbugs & Superdrugs 2018' is in a large, bold, light blue font. Below it, in a smaller white font, is 'Copthorne Tara Hotel, London UK'. A white rounded rectangle contains the dates '19 - 20 MAR'. Below that is the website 'www.superbugssuperdrugs.com' in white. At the bottom, in a white font, is 'Superbugs & Superdrugs Conference'.

Conference is taking place in London on 19 - 20 March. To join and be a part of the global force head on to Superbugs & Superdrugs website to book your attendance  
<http://www.superbugssuperdrugs.com/ein>

## PROGRAMME HIGHLIGHTS:

Analyse the current status of antimicrobial resistance with industry led insight into current strategies to tackle AMR

- Jean-Pierre Paccaud, Director of Business Development at GARDP, Drugs for Neglected Diseases initiative (DNDi) - Day 1, 9:15
- Steve Holden, Medical Adviser, MSD - Day 1, 10:35

Hear exclusive case studies from a selection of pharmaceutical companies on clinical progress

- Conrad Lichtenstein, CSO, Nemesis bioscience - Day 1, 12:15
- David Brown, Managing Director and Founder, Alchemy Biomedical Consulting - Day 1, 12:55
- Learn about regulatory pathways for the registration of new antimicrobial agents:
- Mair Powell, Senior clinical assessor, MHRA - Day 2, 9:50

Evaluate the latest incentives and funding solutions to spur drug discovery:

- Mark Albrecht, Health Scientist, HHS/ASPR/BARDA - Day 1, 9:55
- Adrian Towse, Director, Office of Health Economics - Day 2, 10:30

Explore the latest novel alternatives to antibiotics currently in development:

- Cara Cassino, Chief Medical Officer, ContraFect - Day 2, 15:10
- Stephen Barat, Head of Pre-Clinical and Early Clinical Development, SCYNEXIS Inc - Day 2, 16:20
- Ian Henderson , Professor of Microbial Biology, University Of Birmingham - Day 2, 17:00

View the programme, speaker line-up, and book to attend at

<http://www.superbugssuperdrugs.com/ein>

Superbugs & Superdrugs Team look forward to welcoming you next week to what is shaping up to be another successful show!

Contact:

+44 (0)20 7827 6000

events@smi-online.co.uk

STAY CONNECTED

LinkedIn – search 'SMi Pharma'

Twitter - @SMIpharm #smibugs

-----  
Superbugs & Superdrugs Conference | 19 - 20 March 2018 | London, UK

<http://www.superbugssuperdrugs.com/ein>  
-----

Luda Durneva

SMi Group

email us here

+44 (0)20 7827 6000

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.